Hyponatremia in cirrhosis pathophysiology, prevalence, prognostic value, treatment

Acta Gastro-Enterologica Belgica

Volumn 71, Issue 4, 2008, Pages 379-385

  Moreau, Richard ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ARGIPRESSIN; CONIVAPTAN; CREATININE; DEMECLOCYCLINE; DIURETIC AGENT; LIXIVAPTAN; NIRAVOLINE; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PLACEBO; RMJ 351647; RU 515599; SATAVAPTAN; SODIUM; TOLVAPTAN; UNCLASSIFIED DRUG; UREA; VASOPRESSIN V2 RECEPTOR;

ARTERIAL BLOOD; BLOOD PRESSURE; BLOOD VOLUME; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DEHYDRATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIURESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG WITHDRAWAL; FLUID RESUSCITATION; HEART RATE; HEPATIC ENCEPHALOPATHY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERVOLEMIA; HYPONATREMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIVER TRANSPLANTATION; MICTURITION; NEUROLOGIC DISEASE; ORTHOSTATIC BLOOD PRESSURE; PARACENTESIS; PATHOPHYSIOLOGY; PROGNOSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; THIRST; UNSPECIFIED SIDE EFFECT; VASODILATATION; WATER DEPRIVATION; WATER RETENTION; XEROSTOMIA;

ARGININE VASOPRESSIN; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS;

EID: 60849090468     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. ANGELI P., WONG F., WATSON H., GINÈS P.; CAPPS INVESTIGATORS. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology, 2006, 44: 1535-42.
2. BICHET D., SZATALOWICZ V., CHAIMOVITZ C., SCHRIER R.W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann. Intern. Med., 1982, 96: 413-7.
3. BICHET D.G., VAN PUTTEN V.J., SCHRIER R.W. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N. Engl. J. Med., 1982, 307: 1552-7.
4. ADROGUÉ H.J., MADIAS N.E. Hyponatremia. N. Engl. J. Med., 2000, 342: 1581-9.
5. PORCEL A., DÍAZ F., RENDÓN P., MACÍAS M., MARTÍN-HERRERA L., GIRÓN-GONZÁLEZ J.A. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch. Intern. Med., 2002, 162: 323-8.
6. HEUMAN D.M., ABOU-ASSI S.G., HABIB A., WILLIAMS L.M., STRAVITZ R.T., SANYAL A.J., FISHER R.A., MIHAS A.A. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology, 2004, 40: 802-810.
7. BIGGINS S.W., RODRIGUEZ H.J., BACCHETTI P., BASS N.M., ROBERTS J.P., TERRAULT N.A. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology, 2005, 41: 32-39.
8. RUF A.E., KREMERS W.K., CHAVEZ L.L., DESCALZI V.I., PODESTA L.G., VILLAMIL F.G. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl., 2005, 11: 336-43.
9. BIGGINS SW., KIM WR., TERRAULT NA., SAAB S., BALAN V., SCHIANO T., BENSON J., THERNEAU T., KREMERS W., WIESNER R., KAMATH P., KLINTMALM G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology, 2006, 130: 1652-60.
10. LUCA A., ANGERMAYR B., BERTOLINI G., KOENIG F., VIZZINI G., PLONER M., PECK-RADOSAVLJEVIC M., GRIDELLI B., BOSCH J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl., 2007, 13: 1174-80.
11. SALERNO F., CAMMA C., ENEA M., ROSSLE M., WONG F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology, 2007, 133: 825-834.
12. LONDONO M.C., CARDENAS A., GUEVARA M., DE LAS HERAS D., NAVASA M., RIMOLA A., GARCIA-VALDECASAS J.C., ARROYO V., GINÈS P. Meld score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut, 2007, 56: 1283-90.
13. GINÈS P. Vaptans: a promising therapy in the management of advanced cirrhosis. J Hepatol, 2007, 46: 1150-2.
14. SCHRIER R.W., GROSS P., GHEORGHIADE M., BERL T., VERBALIS J.G., CZERWIEC F.S., ORLANDI C., SALT INVESTIGATORS. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med., 2006, 355: 2099-112.
15. VERBALIS J.G., GOLDSMITH S.R., GREENBERG A., SCHRIER R.W., STERNS R.H. Hyponatremia treatment guidelines, 2007: expert panel recommendations. Am. J. Med., 2007, 120: S1-21.
16. DENNIS G. JR., SHERMAN B.T., HOSACK D.A. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol., 2003, 4: P3.
17. HOLMES C.L., PATEL B.M., RUSSELL J.A., WALLEY K.R. Physiology of vasopressin relevant to management of septic shock. Chest, 2001, 120: 989-1002.
18. FENTON R.A., KNEPPER M.A. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol. Rev., 2007, 87: 1083-112.
19. MOREAU R., LEBREC D. Endogenous factors involved in the control of arterial tone in cirrhosis. J. Hepatol., 1995, 22: 370-6.
20. GADANO A.C., SOGNI P., HELLER J., MOREAU R., BORIES P.N., LEBREC D. Vascular nitric oxide production during the development of two experimental models of portal hypertension. J. Hepatol., 1999, 30: 896-903.
21. MOREAU R., LEE SS., SOUPISON T., ROCHE-SICOT J., SICOT C. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J. Hepatol., 1988, 7: 98-105.
22. FERNANDEZ-SEARA J., PRIETO J., QUIROGA J., ZOZAYA J.M., COBOS MA., RODRIGUEZ-EIRE J.L., GARCIA-PLAZA A., LELA J. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology, 1989, 97: 1304-12.
23. GAUDIN C., BRAILLON A., POO J.L., MOREAU R., HADENGUE A., LEBREC D. Regional sympathetic activity, severity of liver disease and hemodynamics in patients with cirrhosis. J. Hepatol., 1991, 13: 161-8.
24. ROULOT D., MOREAU R., GAUDIN C., BACQ Y., BRAILLON A., HADENGUE A., FROHLY P., LEBREC D. Long-term sympathetic and hemodynamic responses to clonidine in cirrhotic patients with ascites. Gastroenterology, 1992, 102: 1309-18.
25. BRAILLON A., GAUDIN C., POO J.L., MOREAU R., DEBAENE B., LEBREC D. Plasma catecholamine concentrations are a reliable index of sympathetic vascular tone in patients with cirrhosis. Hepatology, 1992, 15: 58-62.
26. MOREAU R., LEBREC D. Transduction of antinatriuretic signals in renal proximal tubular cells in cirrhosis. Introduction to novel approaches to the treatment of sodium retention. J. Hepatol., 1998, 28: 1064-9.
27. GADANO A., MOREAU R., HELLER J., CHAGNEAU C., VACHIÉRY F., TROMBINO C., ELMAN A., DENIÉ C., VALLA D., LEBREC D. Relationship between severity of liver disease and renal oxygen consumption in patients with cirrhosis. Gut, 1999, 45: 117-21.
28. GADANO A., MOREAU R., PESSIONE F., TROMBINO C., GIUILY N., SINNASSAMY P., VALLA D., LEBREC D. Aquaretic effects of niravoline, a k-opioid agonist, in patients with cirrhosis. J. Hepatol., 2000, 32: 38-42.
29. MOREAU R., GAUDIN C., HADENGUE A., BRAILLON A., ROULOT D., BACQ Y., LEBREC D. Renal hemodynamics in patients with cirrhosis: relationship with ascites and liver failure. Nephron, 1993, 65: 359-63.
30. PATERON D., BEYNE P., LAPERCHE T., LEFILIATRE P., SOGNI P., MOREAU R., ELMAN A., BERNUAU J., VALLA D., ERLINGER S., LEBREC D. Elevated circulating troponin I in patients with cirrhosis. Hepatology, 1999, 29: 640-3.
31. MOREAU R., LEBREC D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology, 2006, 43: 385-394.
32. MOORE KP., WONG F., GINES P., BERNARDI M., OCHS A., SALERNO F., ANGELI P., PORAYKO M., MOREAU R., GARCIA-TSAO G., JIMENEZ W., PLANAS R., ARROYO V. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology, 2003, 38: 258-66.
33. MOORE K.P., AITHAL G.P. Guidelines on the management of ascites cirrhosis. Gut, 2006, 55 (Supplement 6): vi1-vi12.
34. KIM W.R., BIGGINS S.W., KREMERS W.K., WIESNER R.H., KAMATH P.S., BENSON J.T., EDWARDS E., THERNEAU T.M. Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med., 2008, 359: 1018-26.
35. BACCARO M.E., GUEVARA M., MARINELLI M., URTASUN SOTIL E., MARTIN-LLAHI M., NAZAR A., ARROYO V., GINÈS P. Clinical characteristics and outcome of hypovolemic hyponatremia in patients with cirrhosis. Comparison with hypervolemic hyponatremia. A prospective study. Proceedings of the Clinical Research Single Topic Conference, AASLD/ EASL, Atlanta, GA, USA, 2008.
36. RESTUCCIA T., GÓMEZ-ANSÓN B., GUEVARA M., ALESSANDRIA C., TORRE A., ALAYRACH M.E., TERRA C., MARTÍN M., CASTELLVÍ M., RAMI L., SAINZ A., GINÈS P., ARROYO V. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology, 2004, 39: 1613-22.
37. RENNEBOOG B., MUSCH W., VANDEMERGEL X., MANTO M.U., DECAUX G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am. J. Med., 2006, 119: 71.e1-8.
38. GINES P., WONG F., MARTIN M., LECORPS G., WATSON H.R. Effects of satavaptan on hyponatremia, management of ascites and morbidity in liver cirrhosis in a long-term placebo-controlled study. Hepatology, 2008, 48 (Suppl.) 413-4A.
39. WONG F., BLEI A.T., BLENDIS L.M., THULUVATH P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology, 2003, 37: 182-91.
40. GERBES A.L., GÜLBERG V., GINÈS P., DECAUX G., GROSS P., GANDJINI H., DJIAN J., VPA STUDY GROUP. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology, 2003, 124: 933-9.
41. GINÈS P., WONG F., WATSON H., MILUTINOVIC S., DEL ARBOL L.R., OLTEANU D., HYPOCAT STUDY INVESTIGATORS. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology, 2008, 48: 204-13.
42. WIESNER R., EDWARDS E., FREEMAN R., HARPER A., KIM R., KAMATH P., KREMERS W., LAKE J., HOWARD T., MERION R.M., WOLFE R.A., KROM R., UNITED NETWORK FOR ORGAN SHARING LIVER DISEASE SEVERITY SCORE COMMITTEE. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003, 124: 91-96.
43. KAMATH P.S., KIM W.R. The Model for End-Stage Liver Disease (MELD). Hepatology, 2007, 45: 797-805.
44. WIJDICKS E.F., BLUE P.R., STEERS J.L., WIESNER R.H. Central pontine myelinolysis with stupor alone after orthotopic liver transplantation. Liver Transpl. Surg., 1996, 2: 14-6.
45. BRONSTER D.J., EMRE S., BOCCAGNI P., SHEINER P.A., SCHWARTZ M.E., MILLER C.M. Central nervous system complications in liver transplant recipients - incidence, timing, and long-term follow-up. Clin. Transplant., 2000, 14: 1-7.
46. ABBASOGLU O., GOLDSTEIN R.M., VODAPALLY M.S., JENNINGS L.W., LEVY M.F., HUSBERG B.S., KLINTMALM G.B. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin. Transplant., 1998, 12: 263-9.
47. LONDOÑO M.C., GUEVARA M., RIMOLA A., NAVASA M., TAURÀ P., MAS A., GARÍA-VALDECASAS J.C., ARROYO V., GINÈS P. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology, 2006, 130: 1135-43.
48. DAWWAS M.F., LEWSEY J.D., NEUBERGER J.M., GIMSON A.E. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl., 2007, 13: 1115-24.